OBR attacked for forecasts ‘free pass’

Revised tax-take predictions strike some economists as odd

Prisoners’ mothers in Saudi Arabia appeal

Local reports say dozens of ‘terrorists’ will soon be executed

Odd office moves reflect shifting London

Exits from traditional commercial centres fired by soaring rents and demand for modern premises

BHP shares fall after UN dam spill report

Mine waste alleged to have contained toxic chemicals and heavy metals

Big bonuses likely for banks’ top talent

Leading performers expected to be rewarded

Barclays pays £72m fine for risk failure

Bank failed to carry out adequate checks on £1.9bn transaction, says FCA

Billionaire arrest widens Petrobras probe

Esteves was face of Brazilian finance during boom years

GSK picks tough China path after scandal

New rules to tackle corrupt practices leave drugmaker at a commercial disadvantage, say industry peers

Saudi counters ‘lower for longer’ mantra

Kingdom shifts message ahead of Opec meeting as investment collapses

Four KPMG partners arrested in Belfast

Move is linked to HMRC investigation into suspected tax evasion

Raspberry Pi bakes up £4 microcomputer

British start-up expands into internet of things

Comment & Analysis

Ingram Pinn illustration, Pfizer
©Ingram Pinn

Big Pharma is addicted to an illusion

Paying high prices for proven drugs and taking a hit to the balance sheet does not avoid the bill

NEW YORK, NY - AUGUST 10: Traders work on the floor of the New York Stock Exchange during the afternoon of August 10, 2015 in New York City. The Dow Jones surged over 230 points after five days of losses. (Photo by Andrew Burton/Getty Images) *** BESTPIX ***

Markets must get used to price quirks

Less capital and more technology are likely to bring more dislocation


The riff: Periods and marketing taboos

A tussle over adverts in New York shows how attitudes must change

Market-moving news and views, 24 hours a day

Sorry, Fast FT is unavailable at the moment


Enter job search